Selected research
Market Structure
Global Age-Related Macular Degeneration (AMD) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Age-Related Macular Degeneration (AMD) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Age-Related Macular Degeneration (AMD) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Age-Related Macular Degeneration (AMD) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Age-Related Macular Degeneration (AMD) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Age-Related Macular Degeneration (AMD) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Age-Related Macular Degeneration (AMD) Therapeutics include Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd. and Bausch Health Companies, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Age-Related Macular Degeneration (AMD) Therapeutics market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Age-Related Macular Degeneration (AMD) Therapeutics and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Age-Related Macular Degeneration (AMD) Therapeutics revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Age-Related Macular Degeneration (AMD) Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.
Age-Related Macular Degeneration (AMD) Therapeutics Segment by Company
Novartis AG
Amgen Inc.
Regeneron Pharmaceuticals Inc.
F. Hoffmann-La Roche Ltd.
Bausch Health Companies, Inc.
Age-Related Macular Degeneration (AMD) Therapeutics Segment by Type
Wet AMD
Dry AMD
Age-Related Macular Degeneration (AMD) Therapeutics Segment by Application
Clinic
Hospital
Research Institute
Other
Age-Related Macular Degeneration (AMD) Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Age-Related Macular Degeneration (AMD) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Age-Related Macular Degeneration (AMD) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Age-Related Macular Degeneration (AMD) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Age-Related Macular Degeneration (AMD) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Age-Related Macular Degeneration (AMD) Therapeutics industry.
Chapter 3: Detailed analysis of Age-Related Macular Degeneration (AMD) Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Age-Related Macular Degeneration (AMD) Therapeuticsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Wet AMD
- Dry AMD
Applications
- Clinic
- Hospital
- Research Institute
- Other
Companies covered
- Novartis AG
- Amgen Inc.
- Regeneron Pharmaceuticals Inc.
- F. Hoffmann-La Roche Ltd.
- Bausch Health Companies, Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Wet AMD
- 1.2.3 Dry AMD
- 1.3 Market Analysis by Application
- 1.3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Clinic
- 1.3.3 Hospital
- 1.3.4 Research Institute
- 1.3.5 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Age-Related Macular Degeneration (AMD) Therapeutics Growth Trends by Region
- 1.5.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2021-2026)
- 1.5.3 Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Dynamics
- 2.1 Age-Related Macular Degeneration (AMD) Therapeutics Industry Trends
- 2.2 Age-Related Macular Degeneration (AMD) Therapeutics Industry Drivers
- 2.3 Age-Related Macular Degeneration (AMD) Therapeutics Industry Opportunities and Challenges
- 2.4 Age-Related Macular Degeneration (AMD) Therapeutics Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Company (2021-2026)
- 3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Key Company Head office and Area Served
- 3.4 Global Age-Related Macular Degeneration (AMD) Therapeutics Company, Product Type & Application
- 3.5 Global Age-Related Macular Degeneration (AMD) Therapeutics Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Age-Related Macular Degeneration (AMD) Therapeutics Players Market Share by Revenue in 2025
- 3.6.3 2025 Age-Related Macular Degeneration (AMD) Therapeutics Tier 1, Tier 2, and Tier 3
4 Age-Related Macular Degeneration (AMD) Therapeutics Market by Type
- 4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2021-2032)
- 4.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Share by Type (2021-2032)
5 Age-Related Macular Degeneration (AMD) Therapeutics Market by Application
- 5.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2021-2032)
- 5.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Novartis AG
- 6.1.1 Novartis AG Company Information
- 6.1.2 Novartis AG Business Overview
- 6.1.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
- 6.1.5 Novartis AG Recent Developments
- 6.2 Amgen Inc.
- 6.2.1 Amgen Inc. Company Information
- 6.2.2 Amgen Inc. Business Overview
- 6.2.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
- 6.2.5 Amgen Inc. Recent Developments
- 6.3 Regeneron Pharmaceuticals Inc.
- 6.3.1 Regeneron Pharmaceuticals Inc. Company Information
- 6.3.2 Regeneron Pharmaceuticals Inc. Business Overview
- 6.3.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
- 6.3.5 Regeneron Pharmaceuticals Inc. Recent Developments
- 6.4 F. Hoffmann-La Roche Ltd.
- 6.4.1 F. Hoffmann-La Roche Ltd. Company Information
- 6.4.2 F. Hoffmann-La Roche Ltd. Business Overview
- 6.4.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
- 6.4.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 6.5 Bausch Health Companies, Inc.
- 6.5.1 Bausch Health Companies, Inc. Company Information
- 6.5.2 Bausch Health Companies, Inc. Business Overview
- 6.5.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
- 6.5.5 Bausch Health Companies, Inc. Recent Developments
7 North America
- 7.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2021-2032)
- 7.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
- 7.2.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2021-2026)
- 7.2.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2027-2032)
- 7.2.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type (2021-2032)
- 7.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
- 7.3.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2021-2026)
- 7.3.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2027-2032)
- 7.3.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application (2021-2032)
- 7.4 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
- 7.4.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2021-2026)
- 7.4.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2027-2032)
- 7.4.4 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2021-2032)
- 8.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
- 8.2.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2021-2026)
- 8.2.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2027-2032)
- 8.2.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type (2021-2032)
- 8.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
- 8.3.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2021-2026)
- 8.3.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2027-2032)
- 8.3.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application (2021-2032)
- 8.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
- 8.4.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2021-2026)
- 8.4.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2027-2032)
- 8.4.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2021-2032)
- 9.2 China Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
- 9.2.1 China Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2021-2026)
- 9.2.2 China Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2027-2032)
- 9.2.3 China Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type (2021-2032)
- 9.3 China Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
- 9.3.1 China Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2021-2026)
- 9.3.2 China Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2027-2032)
- 9.3.3 China Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2021-2032)
- 10.2 Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
- 10.2.1 Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2021-2026)
- 10.2.2 Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2027-2032)
- 10.2.3 Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type (2021-2032)
- 10.3 Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
- 10.3.1 Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2021-2026)
- 10.3.2 Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2027-2032)
- 10.3.3 Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application (2021-2032)
- 10.4 Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
- 10.4.1 Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2021-2026)
- 10.4.3 Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2027-2032)
- 10.4.4 Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
- 11.2.1 South America, Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
- 11.3.1 South America, Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
- 11.4.1 South America, Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst